Hye Ju Shin

Hye Ju Shin

Auto-generated profile, based on publicly available information

Hye Ju Shin

Department of Clinical Drug Discovery & Development, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Obesity
Verified
Journal Article
Open access
HSHye Ju Shin
Hye Ju Shin
CKChan Woo Kang
Chan Woo Kang
EWEun Kyung Wang
Eun Kyung Wang
YKYe Bin Kim
Ye Bin Kim
JNJung Ho Nam
Jung Ho Nam
Cheol Ryong KuCheol Ryong Ku
Cheol Ryong Ku
Objective: We aimed to compare the molecular mechanisms and metabolic outcomes of Roux‐en‐Y gastric bypass (RYGB) and single anastomosis duodeno–ileal bypass with sleeve gastrectomy (SADI‐S) using a preclinical model. Methods: Otsuka Long‐Evans Tokushima Fatty rats with diet‐induced obesity underwent RYGB, SADI‐S, or sham surgery. Metabolic parameters, including glucose tolerance, body weight, and 18F‐fluorodeoxyglucose biodistribution, were assessed at 1‐ and 2‐month postsurgery. The expression of Glucose transporter 1 (GLUT1) and glucose metabolism–related genes in intestinal segments was analyzed. Results: Although RYGB and SADI‐S yielded comparable improvements in glucose tolerance and body weight at 1 month postsurgery, they exerted their effects through distinct mechanisms. RYGB enhanced GLUT1‐mediated glucose excretion in the common limb, whereas SADI‐S upregulated the expression of the glycolytic genes Hk2, Fbp2, Aldob, and Ldha in the colon. Two months postsurgery, the observed metabolic improvements diminished despite sustained weight loss, which coincided with decreased expression of GLUT1 and glycolytic genes. Conclusions: RYGB and SADI‐S achieve similar benefits through distinct glucose handling pathways; however, these effects decline over time. Our data do not support the superiority of SADI‐S over RYGB, particularly given its higher complication rate, and instead highlight the need for strategies aimed at prolonging the therapeutic benefits of metabolic surgeries.